2 recruiting, 1 completed, 1 unknown. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Ataxia Telangiectasia: new trials by email Literature Review of Ataxia Telangiectasia trials Research Report on Ataxia Telangiectasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T) Antisense oligonucleotide targeting the ATM gene - Ataxia Telangiectasia | Phase 1 / Phase 2 | Recruiting | Timothy Yu | 10 | 2026-08-01 | 2026-05-28 |
| An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 266 | 2025-12-03 | 2026-01-28 |
| Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects GTX-102 medium dose fast Period 1 and Period 2, GTX-102 medium dose slow Period 1 and Period 2, GTX-102 high dose fast Period 1 and Period 2 - Ataxia Telangiectasia | Phase 1 | Unknown | Grace Therapeutics Inc. | 48 | 2022-09-13 | 2023-01-23 |
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors | Phase 1 | Completed | Bayer | 56 | 2019-09-30 | 2024-04-02 |
Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Melanoma (1) · Stomach Neoplasms (1)
Ataxia (4) · Brain Diseases (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Cerebellar Ataxia (4) · Cerebellar Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · DNA Repair-Deficiency Disorders (4) · Dyskinesias (4) · Genetic Diseases, Inborn (4) · Immune System Diseases (4) · Immunologic Deficiency Syndromes (4) · Metabolic Diseases (4) · Nervous System Diseases (4) · Neurocutaneous Syndromes (4)
BAY 1895344 (1) · pembrolizumab (1)
Bayer (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · Grace Therapeutics Inc. (1) · Timothy Yu (1)
United States (2) · Canada (1) · China (1) · Germany (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Christelle Achkar, MD (1) · Janice Faulknor, MD (1) · Timothy Yu, MD, PhD (1)
2018 (1)